TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02582983
Drug: Enfuvirtide
Normalized name: Enfuvirtide
DrugBank: Enfuvirtide (DB00109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All participants received enfuvirtide 90 mg SC BID until 4 weeks after commercial availability was established in Thailand.
Study: NCT05348148
Drug: Oral Levocetirizine
DrugBank: Cetirizine (DB00341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be randomly assigned into three groups. Patients in oral Levocetirizine group will use oral antihistamine only (Levocetirizine), another in combined Intranasal Mometasone Furoate with oral Levocetirizine group will use combined intranasal corticosteroids (intranasal Mometasone Furoate) with oral antihistamine (Levocetirizine), and the other in combined Intranasal Mometasone Furoate with oral Levocetirizine plus intranasal Oxymetazoline group will use combined intranasal corticosteroids (intranasal Mometasone Furoate) with oral antihistamine (Levocetirizine) plus one-week intranasal decongestant (intranasal Oxymetazoline).~Digital images and the questionnaires, including PRQLQ, AdolRQLQ, and mini-RQLQ, of every participant will be taken at the beginning of the study. Further assessments will be taken at least 3 times, on the seventh day, fourteenth day, and twenty-eighth day after treatment.
Study: NCT05348148
Drug: Combined Intranasal Mometasone Furoate with oral Levocetirizine
Normalized name: Mometasone Furoate
DrugBank: Cetirizine (DB00341)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will be randomly assigned into three groups. Patients in oral Levocetirizine group will use oral antihistamine only (Levocetirizine), another in combined Intranasal Mometasone Furoate with oral Levocetirizine group will use combined intranasal corticosteroids (intranasal Mometasone Furoate) with oral antihistamine (Levocetirizine), and the other in combined Intranasal Mometasone Furoate with oral Levocetirizine plus intranasal Oxymetazoline group will use combined intranasal corticosteroids (intranasal Mometasone Furoate) with oral antihistamine (Levocetirizine) plus one-week intranasal decongestant (intranasal Oxymetazoline).~Digital images and the questionnaires, including PRQLQ, AdolRQLQ, and mini-RQLQ, of every participant will be taken at the beginning of the study. Further assessments will be taken at least 3 times, on the seventh day, fourteenth day, and twenty-eighth day after treatment.
Study: NCT04074174
Drug: Oral contraceptive (OC) tablets
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet daily on days 1-8 and days 79-86
Study: NCT02355431
Drug: Itacitinib
Normalized name: itacitinib
DrugBank: Itacitinib (DB12154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablets to be administered by mouth once daily at dose selected from safety run-in phase
Study: NCT02355431
Drug: erlotinib
Normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 150 mg tablets administered by mouth once daily at total daily dose of 150 mg
Study: NCT00924326
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Days -5 to -1 (after administration of cyclophosphamide): 25 mg/m\^2 intravenous (IV) over 30 minutes
Study: NCT00924326
Drug: Aldesleukin
Normalized name: Aldesleukin
DrugBank: Aldesleukin (DB00041)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Day 0: 720,000 IU/kg intravenously (IV) every 8 hours for a maximum of 15 doses.
Study: NCT00924326
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Days -5 to -3 (after administration of cyclophosphamide): 30 mg/m\^2 intravenous (IV) over 30 minutes
Study: NCT02164448
Drug: the dexmedetomidine group
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: the dexmedetomidine group: dexmedetomidine infusion from induction of anesthesia to end of surgery
Study: NCT02164448
Drug: the control group
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: saline infusion from induction of anesthesia to end of surgery
Study: NCT01155986
Drug: Lidocaine 5% medicated plaster
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical hydrogel plaster (700mg lidocaine)
Study: NCT05348148
Drug: Combined Intranasal Mometasone Furoate with oral Levocetirizine plus intranasal Oxymetazoline
Normalized name: Mometasone Furoate
DrugBank: Cetirizine (DB00341)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will be randomly assigned into three groups. Patients in oral Levocetirizine group will use oral antihistamine only (Levocetirizine), another in combined Intranasal Mometasone Furoate with oral Levocetirizine group will use combined intranasal corticosteroids (intranasal Mometasone Furoate) with oral antihistamine (Levocetirizine), and the other in combined Intranasal Mometasone Furoate with oral Levocetirizine plus intranasal Oxymetazoline group will use combined intranasal corticosteroids (intranasal Mometasone Furoate) with oral antihistamine (Levocetirizine) plus one-week intranasal decongestant (intranasal Oxymetazoline).~Digital images and the questionnaires, including PRQLQ, AdolRQLQ, and mini-RQLQ, of every participant will be taken at the beginning of the study. Further assessments will be taken at least 3 times, on the seventh day, fourteenth day, and twenty-eighth day after treatment.
Study: NCT00509067
Drug: Galantamine
Normalized name: Galantamine
DrugBank: Galantamine (DB00674)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Galantamine will be titrated to 24 mg/day over 2 weeks. Participants will receive 8 mg/day in two divided doses for 1 week, 16 mg/day in two divided doses for 1 week, and 24 mg/day in two divided doses beginning in Week 3. They will be maintained on 24 mg/day for the remainder of the study.
Study: NCT00509067
Drug: CDP-choline
Normalized name: CDP-choline
DrugBank: Citicoline (DB12153)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDP-choline will serve as the dietary source of choline. CDP-choline will be titrated to 2000 mg/day over 1 week. Subjects will receive 500 mg/day for 3 days; Thereafter, the dose of CDP-choline will be increased to 1,000 mg/day in two divided doses for 4 days. At the beginning of Week 2, participants will receive the maximum fixed dose of 2000 mg/day in two divided doses, which will be held constant through the end of Week 16.
Study: NCT00509067
Drug: risperidone, olanzapine, quetiapine, ziprasidone, and/or aripiprazole
DrugBank: Ziprasidone (DB00246)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All participants will continue to take their regular regimen of risperidone, olanzapine, quetiapine, ziprasidone, and/or aripiprazole throughout the trial in addition to their assigned treatment.
Study: NCT03394144
Drug: AZD9150, Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: After confirmed safety with Cohort 1, Cohort 2 will open. Patients allocated in each cohort will be evaluated for DLT
Study: NCT00131469
Drug: Teriparatide (FORTEO)
Normalized name: TERIPARATIDE (FORTEO) 250MCG/ML (600MCG) INJ,PEN,2.4ML
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Teriparatide (FORTEO) 20mcg, subcutaneous injection, once daily
Study: NCT00574288
Drug: Part 1: Daratumumab
DrugBank: Daratumumab (DB09331)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: First participant will receive intravenous (injection of a substance into a vein) 0.005 milligram per kilogram (mg/kg) (planned dose) infusion of daratumumab and other participants will receive different doses. The participants will receive 7 full infusions of daratumumab and 2 predose infusions every 2 weeks. The dose of daratumumab will be escalated sequentially and considering the safety and efficacy of dose in Part 1, dose for Part 2 of the study will be decided. A predose infusion of 10% of the full dose of daratumumab will be administered a day before the first 2 full infusions.
Study: NCT00574288
Drug: Part 2: Daratumumab
DrugBank: Daratumumab (DB09331)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: In Part 2, the participants will receive dose of daratumumab as determined in part 1 (16 mg/kg) of the study. Participants will receive 8 full infusions at weekly intervals followed by biweekly (every 2 weeks) infusions for 16 additional weeks and monthly infusions until disease progression or unmanageable toxicity, whichever comes first. Predose was dropped at some point in Part 2. A predose infusion of 10 mg daratumumab will be administered on the day before the first full infusion in select cohorts.
Study: NCT02734160
Drug: Galunisertib
Normalized name: Galunisertib
DrugBank: Galunisertib (DB11911)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT02734160
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered IV
Study: NCT02577614
Drug: FEIBA
Normalized name: Feiba
DrugBank: Anti-inhibitor coagulant complex (DB13151)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of FEIBA after cardiopulmonary bypass
Study: NCT00175617
Drug: Minoxidil
Normalized name: Minoxidil
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This study evaluates the efficacy of therapy with the anti-androgen spironolactone compared to topical minoxidil in female pattern hair loss.
Study: NCT00531856
Drug: Inhaled carbon monoxide
Normalized name: carbon monoxide
DrugBank: Carbon monoxide (DB11588)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.7 mg/kg carbon monoxide/placebo over one hour administered 12-48 hours post transplant
Study: NCT00531856
Drug: Inhaled carbon monoxide
Normalized name: carbon monoxide
DrugBank: Carbon monoxide (DB11588)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 mg/kg carbon monoxide/placebo over one hour administered 12-48 hours post transplant
Study: NCT00531856
Drug: Inhaled carbon monoxide
Normalized name: carbon monoxide
DrugBank: Carbon monoxide (DB11588)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.0 mg/kg carbon monoxide/placebo over one hour administered 12-48 hours during transplant
Study: NCT00531856
Drug: Inhaled Carbon Monoxide
Normalized name: carbon monoxide
DrugBank: Carbon monoxide (DB11588)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.5 mg/kg carbon monoxide/placebo over one hour administered 12-48 hours during transplant
Study: NCT00531856
Drug: Inhaled Carbon Monoxide
Normalized name: carbon monoxide
DrugBank: Carbon monoxide (DB11588)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 mg/kg carbon monoxide/placebo over one hour administered 12-48 hours during transplant.
Study: NCT01479179
Drug: AMG 479
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase I Starting Dose: 18 mg/kg by vein on Day 1 of a 21 day cycle.~Phase II Starting Dose: Maximum tolerated dose from Phase I.
Study: NCT03912337
Drug: Erenumab
Normalized name: ERENUMAB
DrugBank: Erenumab (DB14039)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Erenumab once every 4 weeks. SC injection.
Study: NCT01479179
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Phase I and II Starting Dose: 8 mg/kg by vein on Day 1 of a 21 day cycle.~Phase I and II Maintenance Dose: 6 mg/kg by vein on Day 1 of a 21 day cycle.
Study: NCT02871778
Drug: VX-371
Normalized name: VX-121
DrugBank: Vanzacaftor (DB18373)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02871778
Drug: VX-371 + HS
Normalized name: VX-121
DrugBank: Vanzacaftor (DB18373)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02871778
Drug: Ivacaftor
Normalized name: Ivacaftor
DrugBank: Ivacaftor (DB08820)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01568398
Drug: TAK-438
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02134080
Drug: PF-04457845
Normalized name: PF-04457845
DrugBank: PF-04457845 (DB12012)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-04457845 will be administered orally at 4mg daily for four weeks.
Study: NCT03184480
Drug: Arnuity Ellipta
Normalized name: Arnuity Ellipta
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The active component of Arnuity Ellipta is fluticasone furoate and it is indicated for the treatment of bronchial asthma. Post-marketing investigation of ARNUITY ELLIPTA will be carried out in this analysis.
Study: NCT02261779
Drug: Tranylcypromine
Normalized name: Tranylcypromine
DrugBank: Tranylcypromine (DB00752)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00990054
Drug: Plerixafor
Normalized name: Plerixafor
DrugBank: Plerixafor (DB06809)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 240 mcg/kg/dose and proceeding to escalating dose levels for determination of the single-dose maximum tolerated dose (MTD) provided that there are no unacceptable dose limiting toxicities
Study: NCT00356889
Drug: erlotinib hydrochloride
Normalized name: Erlotinib Hydrochloride
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally, 150 mg, once daily.
Study: NCT00163462
Drug: Ciclesonide
Normalized name: Ciclesonide
DrugBank: Ciclesonide (DB01410)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02107092
Drug: Sodium Zirconium Cyclosilicate
Normalized name: sodium zirconium cyclosilicate
DrugBank: Sodium zirconium cyclosilicate (DB14048)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral 10g once daily with breakfast for 11 months.
Study: NCT01386294
Drug: Tenofovir gel
Normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tenofovir gel is a clear, transparent, viscous gel at concentrations of 1% formulated in purified water with edentate disodium, citric acid, glycerin, methylparaben, propylparaben, HEC, and pH adjusted to 4-5. Tenofovir gel will be supplies in a 4 ml single use applicator containing approximately 4 grams of gel, equivalent to approximately 40mg of tenofovir.
Study: NCT01587339
Drug: retigabine/ezogabine
DrugBank: Ezogabine (DB04953)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral - all doses
Study: NCT01587339
Drug: lacosamide
Normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: oral - all doses
Study: NCT01587339
Drug: zonisamide
Normalized name: Zonisamide
DrugBank: Zonisamide (DB00909)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: oral - all doses
Study: NCT01587339
Drug: pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: oral - all doses
Study: NCT01587339
Drug: eslicarbazepine
Normalized name: Eslicarbazepine
DrugBank: Eslicarbazepine acetate (DB09119)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral - all doses
Study: NCT01638078
Drug: Thalidomide
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Thalidomide, pill, 50 mg, once p.d., 6 weeks
Study: NCT01466530
Drug: Misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sublingual misoprostol was given by putting two moistened tablets of misoprostol (400 µg) under the tongue and allowing them to dissolve (Misotac®, Sigma Pharmaceutical Industries, Egypt) (200 µg/tablet).
Study: NCT02581748
Drug: HLX02
Normalized name: Trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02581748
Drug: Herceptin
Normalized name: Herceptin
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00537030
Drug: Asparaginase
Normalized name: Asparaginase
DrugBank: Asparaginase Escherichia coli (DB00023)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IM
Study: NCT00517322
Drug: ramipril
Normalized name: Ramipril
DrugBank: Ramipril (DB00178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ramipril 2.5- 5 mg once daily
Study: NCT00517322
Drug: irbesartan
Normalized name: Irbesartan
DrugBank: Irbesartan (DB01029)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: irbesartan 150-300 mg once daily
Study: NCT00419146
Drug: Ethyl-eicosapentaenoic acid (EPA)
Normalized name: Ethyl eicosapentaenoate
DrugBank: Icosapent ethyl (DB08887)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Capsules, 2 g per day for 16 weeks
Study: NCT00419146
Drug: Vitamins E + C
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: RRR-alpha-tocopherol 392 mg + slow-release ascorbic acid 1000 mg per day, for 16 weeks
Study: NCT00414765
Drug: Aldesleukin
Normalized name: Aldesleukin
DrugBank: Aldesleukin (DB00041)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00148772
Drug: Erlotinib (Tarceva)
Normalized name: erlotinib Oral Tablet [Tarceva]
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00053924
Drug: perifosine
Normalized name: Perifosine
DrugBank: Perifosine (DB06641)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01543828
Drug: indacaterol
Normalized name: Indacaterol
DrugBank: Indacaterol (DB05039)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: delivered via single-dose dry-powder inhaler
Study: NCT01925898
Drug: Midazolam - active comparator
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral midazolam - 0.7mg/kg single dose
Study: NCT01925898
Drug: Experimental Arm: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Ketamine 5mg/kg Single dose
Study: NCT00073528
Drug: Lapatinib
Normalized name: Lapatinib
DrugBank: Lapatinib (DB01259)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1500 mg orally once a day
Study: NCT00073528
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2.5 mg orally once a day
Study: NCT00193141
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00193141
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00193141
Drug: 5-Fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04625114
Drug: Camostat
Normalized name: camostat
DrugBank: Camostat (DB13729)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care (SOC) + Camostat mesilate (Foipan) 100mg 3 tablets 3 times a day for 5 consecutive days (D1-\>D5);
Study: NCT04625114
Drug: Camostat
Normalized name: camostat
DrugBank: Camostat (DB13729)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care (SOC) + Camostat mesilate (Foipan) 100mg 3 tablets 3 times a day for 5 consecutive days (D6-\>D10);
Study: NCT01866449
Drug: Cabazitaxel
Normalized name: Cabazitaxel
DrugBank: Cabazitaxel (DB06772)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01733966
Drug: Secnidazole, ciprofloxacine
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2g of microgranules of secnidazole. a single dose per day during 3 days.~1g of Ciprofloxacin (2 tablets of 500mg per day during 3 days)
Study: NCT01733966
Drug: Amoxicillin-Clavulanic Acid
Normalized name: amoxicillin / clavulanate
DrugBank: Clavulanic acid (DB00766)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3g of Amoxicillin-Clavulanic acid (3 powder packet of 1g per day during 10 days)
Study: NCT01023867
Drug: donepezil
Normalized name: Donepezil
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: from 5mg to 10mg, once a day, 12 months
Study: NCT00535275
Drug: Chemotherapy without Cisplatine
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 75 mg/m² D1 (D1=D22, 4 cycles) Docetaxel 75 mg/m² D1 (D1=D22, 2 cycles if disease control)
Study: NCT02096510
Drug: Solu-Cortef
Normalized name: Solu-Cortef
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: administration by pump for minimum 2 weeks
Study: NCT02096510
Drug: Cortef
Normalized name: Cortef
DrugBank: Hydrocortisone (DB00741)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: tablet treatment 2 ro 3 times per day for 14 days
Study: NCT00258271
Drug: cladribine
Normalized name: Cladribine
DrugBank: Cladribine (DB00242)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00258271
Drug: cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03295851
Drug: Ferric carboxymaltose
Normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients in the intervention group will receive preoperative IV ferric carboxymaltose, given as a single dose (15 mg/kg body weight, to a maximum dose of 1000 mg) over 30 minutes.
Study: NCT03295851
Drug: Ferrous Fumarate
Normalized name: Ferrous Fumarate
DrugBank: Ferrous tartrate (DB13639)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be given oral iron as per current clinical protocol, which is Ferrous fumarate 200mg twice daily.
Study: NCT02721888
Drug: Liraglutide
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00258271
Drug: imatinib mesylate
Normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00733954
Drug: clobetasol propionate spray
Normalized name: clobetasol propionate Topical Spray
DrugBank: Clobetasol propionate (DB01013)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Apply twice daily
Study: NCT00733954
Drug: clobetasol propionate ointment
Normalized name: Clobetasol Propionate Ointment
DrugBank: Clobetasol propionate (DB01013)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Apply twice daily
Study: NCT00225979
Drug: Octreotide LAR
Normalized name: octreotide LAR 20 MG Injection
DrugBank: Octreotide (DB00104)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01056172
Drug: Peginterferon alfa-2a and Ribavirin
Normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1. PegIFN alfa-2a (PEgasys) 180 ug/week~2. Weight-based ribavirin (\<65kg: 800mg/day, 65-85kg: 1000mg/day, \>85kg: 1200mg/day)~3. Treatment duration: 16 weeks
Study: NCT01056172
Drug: Peginterferon alfa-2a and Ribavirin
Normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1. PegIFN alfa-2a (PEgasys) 180 ug/week~2. Weight-based ribavirin (\<65kg: 800mg/day, 65-85kg: 1000mg/day, \>85kg: 1200mg/day)~3. Treatment duration: 24 weeks
Study: NCT00602095
Drug: misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.025mg tablet vaginally every 4 hour until progress
Study: NCT04417179
Drug: Bupivacaine 0.25% Injectable Solution
Normalized name: BUPivacaine 0.25% injectable solution
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local Anesthetic used in both blocks
Study: NCT00962442
Drug: N-Acetylcysteine
Normalized name: N-acetylcysteine
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 300 mg/kg for 14 days, intravenously
Study: NCT00681174
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.15 mg/kg i.v. bolus, 30 minutes before the expected end of anesthesia